Eli Lilly & Co. (LLY) Tops Q4 EPS by 21c, Updates FY Guidance

Eli Lilly & Co. (NYSE: LLY) reported Q4 EPS of $1.73, $0.21 better than the analyst estimate of $1.52. Revenue for the quarter came in at $6.11 billion versus the consensus estimate of $5.91 billion.

GUIDANCE:

Eli Lilly & Co. sees FY2020 EPS of $6.70-$6.80, versus the consensus of $6.76. Eli Lilly & Co. sees FY2020 revenue of $23.7-24.2 billion, versus the consensus of $23.82 billion.

For earnings history and earnings-related data on Eli Lilly & Co. (LLY) click here.

You May Also Be Interested In

• Eli Lilly: Q2 2026 IPR&D charge estimated at $3.02 per share on GAAP and non-GAAP basis
• Helen of Troy (HELE) Tops Q1 EPS by 22c, Beats on Revenue; Offers FY Guidance
• Eli Lilly (LLY) PT Raised to $1,500 at RBC Capital